← Guides / Australia

Australia Pharma & Life Sciences Tax Guide

Australian tax rules for the pharmaceutical and life sciences industry. The guide covers: the R&D Tax Incentive for the pharma and the biotech — the 'pharmaceutical and the life sciences companies' (the 'drug developers', the 'biotech companies', the 'medical device companies') are the 'major beneficiaries' of the 'R&D Tax Incentive' — the 'refundable R&D tax offset at 43.5% for the SMEs (the turnover below $20 million)' and the 'non-refundable R&D tax offset at 38.5% for the large companies (the turnover of $20 million or more)'; the 'R&D activities' in the 'pharma and the life sciences' include: (i) the 'drug discovery and the development', (ii) the 'clinical trials' (the 'Phase I, II, III, and IV clinical trials'), (iii) the 'medical device development', (iv) the 'diagnostic test development', (v) the 'biotechnology research', (vi) the 'regulatory testing and the stability studies'; the 'R&D expenditure' includes the 'labour costs', the 'clinical trial costs', the 'consumables', the 'feedstock', and the 'contract research costs'; the patent box (the 'corporate tax rate of 17% on the patent income') — the 'Australian patent box' (the 'tax concession for the patent income') was 'announced in the 2024-25 Budget' and 'applies from the 1 July 2024'; the 'patent box' 'taxes the corporate income from the Australian medical and the biotechnology patents at the 'effective corporate tax rate of 17%' (the 'concessional rate of 17%' instead of the 'standard rate of 25% or 30%'); the 'patent box' applies to the 'income from the Australian medical and the biotech patents' that are 'granted by the IP Australia' and the 'R&D is conducted in Australia'; the 'patent box' is the 'tax incentive' for the 'Australian medical and the biotech innovation'; the clinical trial incentives — the 'clinical trial tax incentives' include: (i) the 'R&D Tax Incentive for the clinical trial costs' (the 'clinical trial expenditure is the eligible R&D expenditure'), (ii) the 'Clinical Trial Notification Scheme (the 'CTN')' and the 'Clinical Trial Approval Scheme (the 'CTA')' under the 'Therapeutic Goods Administration (the 'TGA')' — the 'tax deduction for the clinical trial costs' under the 'Section 8-1 of the ITAA 1997'; the biotech tax concessions and the grants — the 'biotech companies' may be eligible for: (i) the 'Early Stage Innovation Company (ESIC) tax incentives' — the '30% non-refundable tax offset' and the '10-year CGT exemption' for the 'investors in the ESICs', (ii) the 'Biotechnology Innovation Grant' (the 'state government grants' for the 'biotech R&D and the commercialisation'), (iii) the 'Medical Research Future Fund (the 'MRFF')' — the 'government fund for the medical research and the innovation'.

R&D for Pharma & Biotech

  • Refundable offset at 43.5%: The 'SME pharma companies' (the 'turnover below $20 million') receive the 'refundable R&D offset at 43.5%'.
  • Non-refundable offset at 38.5%: The 'large pharma companies' (the 'turnover of $20 million or more') receive the 'non-refundable R&D offset at 38.5%'.
  • Clinical trial costs: The 'clinical trial expenditure' (the 'Phase I to IV trials') is the 'eligible R&D expenditure'.

For the R&D Tax Incentive and the registration requirements, see our R&D Tax Guide →.

Patent Box

  • 17% corporate tax rate: The 'income from the Australian medical and the biotech patents' is 'taxed at 17%' (from the '1 July 2024').
  • Eligible patents: The 'Australian patents granted by the IP Australia' for the 'medical and the biotechnology inventions'.
  • R&D conducted in Australia: The 'R&D for the patented invention' must be 'conducted in Australia' to 'qualify for the patent box'.

For the corporate tax rates and the company tax returns, see our Corporate Tax Guide →.

ESIC & Biotech Grants

  • ESIC incentives: The 'investors in the early stage biotech companies' receive the '30% tax offset' and the '10-year CGT exemption'.
  • MRFF grants: The 'Medical Research Future Fund' provides the 'grants for the medical research and the commercialisation'.

For the ESIC tax incentives and the venture capital, see our Venture Capital & ESIC Guide →.